AU2013243737B2 - Tyrosine kinase inhibitor combinations and their use - Google Patents

Tyrosine kinase inhibitor combinations and their use Download PDF

Info

Publication number
AU2013243737B2
AU2013243737B2 AU2013243737A AU2013243737A AU2013243737B2 AU 2013243737 B2 AU2013243737 B2 AU 2013243737B2 AU 2013243737 A AU2013243737 A AU 2013243737A AU 2013243737 A AU2013243737 A AU 2013243737A AU 2013243737 B2 AU2013243737 B2 AU 2013243737B2
Authority
AU
Australia
Prior art keywords
tyrosine kinase
combination
met
fgfr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013243737A
Other languages
English (en)
Other versions
AU2013243737A1 (en
Inventor
Alan Buckler
Fred HARBINSKI
Douglas Jeffery
Sneha SANGHAVI
Ralph TIEDT
Christopher Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013243737A1 publication Critical patent/AU2013243737A1/en
Application granted granted Critical
Publication of AU2013243737B2 publication Critical patent/AU2013243737B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013243737A 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use Ceased AU2013243737B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
US61/619,502 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (2)

Publication Number Publication Date
AU2013243737A1 AU2013243737A1 (en) 2014-09-25
AU2013243737B2 true AU2013243737B2 (en) 2016-06-30

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013243737A Ceased AU2013243737B2 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Country Status (11)

Country Link
US (1) US20150051210A1 (enExample)
EP (1) EP2833917A1 (enExample)
JP (1) JP2015512447A (enExample)
KR (1) KR20140146086A (enExample)
CN (1) CN104244982A (enExample)
AU (1) AU2013243737B2 (enExample)
CA (1) CA2866321A1 (enExample)
IN (1) IN2014DN07410A (enExample)
MX (1) MX2014011987A (enExample)
RU (1) RU2014143213A (enExample)
WO (1) WO2013151913A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
US10195208B2 (en) * 2014-07-31 2019-02-05 Novartis Ag Combination therapy
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
CA2683559C (en) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
BR112012003262A8 (pt) * 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KENTSIS, A et al (2011) Blood (ASH Annual Meeting Abstracts) 118: Abstract 1405 *

Also Published As

Publication number Publication date
CA2866321A1 (en) 2013-10-10
IN2014DN07410A (enExample) 2015-04-24
KR20140146086A (ko) 2014-12-24
US20150051210A1 (en) 2015-02-19
JP2015512447A (ja) 2015-04-27
MX2014011987A (es) 2014-11-10
EP2833917A1 (en) 2015-02-11
CN104244982A (zh) 2014-12-24
RU2014143213A (ru) 2016-05-27
WO2013151913A1 (en) 2013-10-10
AU2013243737A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP6532878B2 (ja) 組合せ医薬
WO2023190748A1 (ja) 腫瘍治療用医薬組成物
KR20240024938A (ko) Kras g12c 저해제를 포함하는 약제학적 조합물 및 암의 치료를 위한 이의 용도
EP2834246B1 (en) Combination products with tyrosine kinase inhibitors and their use
TW202045171A (zh) 包含tno155和瑞博西尼之藥物組合
US10881664B2 (en) Methods for treating EGFR mutant cancers
KR20120115237A (ko) 암 치료 방법 및 조성물
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
Zhang et al. Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
US20150051210A1 (en) Tyrosine Kinase Inhibitor Combinations and their Use
JP2020529411A (ja) 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ
JP2024521788A (ja) 併用療法
US10792277B2 (en) Methods of treatment of fibrosis and cancers
JP2011509931A (ja) 癌を処置するための組成物および方法
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
JP6526789B2 (ja) 組み合わせ療法
JP2023524789A (ja) Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ
US20250032458A1 (en) Treatment of cancer with an fgfr kinase inhibitor
WO2024220421A1 (en) Treatment of cancer with a met kinase inhibitor
US9956221B2 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease
Na et al. Anlotinib: A Novel Molecular-Targeted Drug for Tumours
WO2026018023A1 (en) Synergistic combinations comprising lunbotinib for anti-cancer therapy
Mila et al. 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, California, USA-April 5-9, 2014
HK1240924B (en) A deuterated triazolopyridazine as a kinase modulator

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired